Checkpoint Therapeutics (NASDAQ:CKPT) Earns “Buy” Rating from D. Boral Capital

Checkpoint Therapeutics (NASDAQ:CKPT)‘s stock had its “buy” rating restated by equities research analysts at D. Boral Capital in a research report issued on Monday,Benzinga reports. They presently have a $4.80 target price on the stock. D. Boral Capital’s target price points to a potential upside of 18.81% from the stock’s current price.

A number of other analysts also recently issued reports on CKPT. HC Wainwright restated a “neutral” rating and issued a $4.10 price target on shares of Checkpoint Therapeutics in a research report on Tuesday, March 11th. Lake Street Capital reissued a “hold” rating and issued a $4.10 target price (down previously from $7.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th.

Checkpoint Therapeutics Stock Performance

Shares of NASDAQ CKPT opened at $4.04 on Monday. Checkpoint Therapeutics has a 12-month low of $1.38 and a 12-month high of $4.50. The firm’s 50-day moving average price is $3.35 and its 200-day moving average price is $3.29. The stock has a market capitalization of $197.29 million, a price-to-earnings ratio of -2.20 and a beta of 1.41.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its quarterly earnings data on Friday, March 28th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.47). On average, equities analysts predict that Checkpoint Therapeutics will post -0.94 EPS for the current fiscal year.

Insider Activity

In other news, CEO James F. Oliviero III sold 10,331 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $3.15, for a total transaction of $32,542.65. Following the transaction, the chief executive officer now directly owns 3,775,019 shares of the company’s stock, valued at approximately $11,891,309.85. This trade represents a 0.27 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO William Garrett Gray sold 74,110 shares of Checkpoint Therapeutics stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $3.67, for a total transaction of $271,983.70. Following the sale, the chief financial officer now directly owns 1,458,644 shares of the company’s stock, valued at $5,353,223.48. This represents a 4.84 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 93,674 shares of company stock valued at $336,011. 2.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Ameriflex Group Inc. purchased a new stake in shares of Checkpoint Therapeutics in the 4th quarter worth $32,000. PUREfi Wealth LLC purchased a new position in shares of Checkpoint Therapeutics during the fourth quarter valued at $32,000. SBI Securities Co. Ltd. bought a new stake in shares of Checkpoint Therapeutics in the fourth quarter valued at about $32,000. Stifel Financial Corp purchased a new stake in Checkpoint Therapeutics in the fourth quarter worth about $32,000. Finally, Tower Research Capital LLC TRC grew its holdings in Checkpoint Therapeutics by 157.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,616 shares of the company’s stock worth $34,000 after acquiring an additional 6,486 shares in the last quarter. 22.00% of the stock is currently owned by hedge funds and other institutional investors.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.